APAC Multiple Sclerosis Treatment Market Segmented, by Disease Type (RelapsingRemitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), Severe RelapsingRemitting Multiple Sclerosis (RES)),by Treatment (Preventive Therapies, Abortive Therapies/Treatment of Acute Exacerbations, Symptomatic Therapies), by Drug Type (Branded, Generic), by Route of Administration (Oral, Parenteral), by End-User (Hospital, Homecare, Specialty Centres, Others), and by Distribution Channel (Retail Sales, Direct Tender)- Growth, Trends and Forecast, 2019-2028
- Published Date: 2022-12-26
- Report ID: 138315
- Pages: 200
-
Format:
Report Overview
The APAC Multiple Sclerosis Treatment Market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 8.5% during the forecast period
Multiple sclerosis is a chronic, inflammatory,autoimmune disorder that affects the (CNS) central nervous system, especially the communication between the brain and other areas of the body. Multiple sclerosis (MS) in particular is a demyelinating disease that damages the insulating covers of nerve cells in the brain and spinal cord. There is usually no cure for MS, general care is based on speedy recovery from damage that delays disease progression and manages MS symptoms
Market Drivers
The rising number of patients, increased screening and the need for better care options are thought to be the key factors for the multiple sclerosis treatment market growth during the forecast period. In ageing population, the disease is more prone, hence the surge in the geriatric population further escalates the multiple sclerosis treatment market growth
1. APAC Multiple Sclerosis Treatment Market Overview
A. Market Size
2. APAC Multiple Sclerosis Treatment Growth Drivers
A. The rising number of patients, increased screening and the need for better care options
B. In ageing population, the disease is more prone, hence the surge in the geriatric population
3. APAC Multiple Sclerosis Treatment Segmentation
A. By Disease Type
I. RelapsingRemitting Multiple Sclerosis (RRMS)
II. Secondary Progressive Multiple Sclerosis (SPMS)
III. Primary Progressive Multiple Sclerosis (PPMS)
IV. Severe RelapsingRemitting Multiple Sclerosis (RES)
B. By Treatment
I. Preventive Therapies
II. Abortive Therapies/Treatment of Acute Exacerbations
III. Symptomatic Therapies
C. By Drug Type
I. Branded
II. Generic
D. By Route of Administration
I. Oral
II. Parenteral
E. By End-User
I. Hospital
II. Homecare
III. Specialty Centres
IV. Others
F. By Distribution Channel
I. Retail Sales
II. Direct Tender
4. APAC Multiple Sclerosis Treatment Market Share
A. Market Analysis, Insights and Forecast by Revenue
5. Competitive Landscape
A. Major Players
B. Products in Pipeline
6. Key Company Profiles..
A. Genzyme Corporation, Company overview, Product & Services, Strategies & Financials
B. Teva Pharmaceuticals, Company overview, Product & Services, Strategies & Financials
C. Merck KGaA, Company overview, Product & Services, Strategies & Financials
7. Healthcare Policies and Regulatory Landscape.
A. Policy Changes and Reimbursement Scenario
8. Factors Driving Market Growth
A. Key Industry Developments
B. Mergers and Acquisitions
9. Potential Growth Opportunities
A. Market Opportunities
B. Future Trends
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
